MARKET

RTRX

RTRX

Retrophin
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.63
+0.50
+3.30%
After Hours: 15.63 0 0.00% 16:00 04/08 EDT
OPEN
15.36
PREV CLOSE
15.13
HIGH
15.93
LOW
15.01
VOLUME
423.13K
TURNOVER
--
52 WEEK HIGH
23.26
52 WEEK LOW
8.98
MARKET CAP
673.90M
P/E (TTM)
-4.5111
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average RTRX stock price target is 28.57 with a high estimate of 35.00 and a low estimate of 19.00.

EPS

RTRX News

More
  • Do Options Traders Know Something About Retrophin (RTRX) Stock We Don't?
  • Zacks · 03/18 14:01
  • Retrophin Announces Enrollment of First 190 Patients in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
  • GlobeNewswire · 03/09 13:00
  • Edited Transcript of RTRX earnings conference call or presentation 24-Feb-20 9:30pm GMT
  • Thomson Reuters StreetEvents · 03/08 21:09
  • Retrophin Recognizes Rare Disease Day 2020 and the Importance of Working Together Toward More Equitable Access to Care
  • GlobeNewswire · 02/28 13:00

Industry

Biotechnology & Medical Research
+3.08%
Pharmaceuticals & Medical Research
+2.83%

Hot Stocks

Symbol
Price
%Change

About RTRX

Retrophin, Inc. is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.
More

Webull offers kinds of Retrophin Inc stock information, including NASDAQ:RTRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RTRX stock news, and many more online research tools to help you make informed decisions.